
GLP-1 drugs raised testosterone; normal levels rose from 67% to 86% of men with obesity
Karl Nadolsky shares a real-world study where incretin-based drugs in men with obesity produced modest weight loss, better glycemic control and higher total and free testosterone, most in those who lost the most weight. Louis argues GLP-1s treat the root cause (visceral fat) of low testosterone, unlike TRT.
